Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG00011 (STX-100) in Idiopathic Pulmonary Fibrosis
NCT03573505Phase 2Terminated
- Sponsor
- Biogen
- Start
- Sep 2018
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BG00011 Arm with Placebo Arm (2 arms). Primary endpoint: Change From Baseline in Forced (Expiratory) Vital Capacity (FVC) at 52 weeks. Started Sep 2018; status: terminated.
02
Drugs
STX-100
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03573505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573505.